Welcome to our dedicated page for Defence Therapeu news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on Defence Therapeu stock.
Defence Therapeutics Inc. reports developments in biotechnology and precision intracellular drug delivery through its proprietary Accum® platform. Company news centers on cancer-therapy applications, including antibody-drug conjugates, radiopharmaceutical and radio-immunoconjugate programs, and other complex biologics designed for intracellular and nuclear delivery.
Recurring updates also cover scientific advisory activity, industry presentations, collaboration work such as its program with Canadian Nuclear Laboratories, partnership outreach, and capital-structure actions including private placements, warrant amendments, and restricted stock unit grants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.